The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.i

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

Publications

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC

Safety-related regulatory actions for biologicals approved in the United States and the European Union.

JAMA 2008 Oct 22;300;1887-96 — 2008 Oct 22 — 1887-96

Lenz HJ

Management and preparedness for infusion and hypersensitivity reactions.

The oncologist 2007 May;12;601-9 — 2007 May — 601-9

Tada K, Ito Y, Hatake K, Okudaira T, Watanabe J, Arakawa M, Miyazato M, Irie T, Mizunuma N, Takahashi S, Aiba K, Horikoshi N, Kasumi F

Severe infusion reaction induced by trastuzumab: a case report.

Breast cancer (Tokyo, Japan) 2003;10;167-9 — 2003 — 167-9